home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409c.zip
/
M9490413.TXT
< prev
next >
Wrap
Text File
|
1994-09-19
|
3KB
|
51 lines
Document 0413
DOCN M9490413
TI Immunization with a soluble CD4-gp120 complex preferentially induces
neutralizing anti-human immunodeficiency virus type 1 antibodies
directed to conformation-dependent epitopes of gp120.
DT 9411
AU Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP; IDEC
Pharmaceuticals Corporation, San Diego, California 92121.
SO J Virol. 1994 Sep;68(9):5854-62. Unique Identifier : AIDSLINE
MED/94335102
AB Preservation of the conformation of recombinant gp120 in an adjuvant,
enabling it to elicit conformation-dependent, epitope-specific, broadly
neutralizing antibodies, may be critical for the development of any
gp120-based human immunodeficiency virus type 1 (HIV-1) vaccine. It was
hypothesized that recombinant gp120 complexed with recombinant CD4 could
stabilize the conformation-dependent neutralizing epitopes and
effectively deliver them to the immune system. Therefore, a soluble
CD4-gp120 complex in Syntex adjuvant formulation was tested with mice
for its ability to induce neutralizing anti-gp120 antibody responses.
Seventeen monoclonal antibodies (MAbs) were generated and characterized.
Immunochemical studies, neutralization assays, and mapping studies with
gp120 mutants indicated that the 17 MAbs fell into three groups. Four of
them were directed to what is probably a conformational epitope
involving the C1 domain and did not possess virus-neutralizing
activities. Another four MAbs bound to V3 peptide 302-321 and exhibited
cross-reactive gp120 binding and relatively weak virus-neutralizing
activities. These MAbs were very sensitive to amino acid substitutions,
not only in the V3 regions but also in the base of the V1/V2 loop,
implying a conformational constraint on the epitope. The last group of
nine MAbs recognized conformation-dependent epitopes near the CD4
binding site of gp120 and inhibited the gp120-soluble CD4 interaction.
Four of these nine MAbs showed broadly neutralizing activities against
multiple laboratory-adapted strains of HIV-1, three of them neutralized
only HIVIIIB, and the two lower-affinity MAbs did not neutralize any
strain tested. Collectively, the results from this study indicate that
immunization with the CD4-gp120 complex can elicit antibodies to
conformationally sensitive gp120 epitopes, with some of the antibodies
having broadly neutralizing activities. We suggest that immunization
with CD4-gp120 complexes may be worth evaluating further for the
development of an AIDS vaccine.
DE Animal Antibodies, Monoclonal/IMMUNOLOGY Antigenic Determinants
Antigens, CD4/*IMMUNOLOGY HIV Antibodies/*IMMUNOLOGY HIV Envelope
Protein gp120/*IMMUNOLOGY/ULTRASTRUCTURE HIV-1/*IMMUNOLOGY
Macromolecular Systems Mice Mice, Inbred BALB C Neutralization Tests
Protein Binding Protein Conformation Recombinant Proteins Solubility
Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).